# Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome

Study · id `cardio:ct-nct02446730` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02446730](<https://clinicaltrials.gov/study/NCT02446730>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02446730

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1400 participants.

## Technical summary

Registry record NCT02446730. Randomized; no masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2017-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1400 participants (planned count; ClinicalTrials.gov record NCT02446730, source copy `cardio:ctgov-nct02446730-2015-05-18`, retrieved 2026-10-26)
- Start date: 2014-09 (registry gives no type) (ClinicalTrials.gov record NCT02446730, source copy `cardio:ctgov-nct02446730-2015-05-18`, retrieved 2026-10-26)
- Primary completion: 2017-08 (anticipated) (ClinicalTrials.gov record NCT02446730, source copy `cardio:ctgov-nct02446730-2015-05-18`, retrieved 2026-10-26)
- Completion: 2017-08 (anticipated) (ClinicalTrials.gov record NCT02446730, source copy `cardio:ctgov-nct02446730-2015-05-18`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02446730, source copy `cardio:ctgov-nct02446730-2015-05-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02446730-2015-05-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
- Acronym: BEAUTY-II
- Condition: Cardiac Death
- Condition: Hemorrhage
- Condition: Cerebrovascular Accident
- Condition: Myocardial Infarction
- Intervention (Device): BES (biodegradable polymer biolimus-eluting stent)
- Intervention (Drug): Prasugel
- Intervention (Drug): Clopidogrel
- Lead sponsor: Chonnam National University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Chonnam National University Hospital (`cardio:org-chonnam-national-university-hospital`)

## Provenance

Content hash: b57b50231cf587028f9aaecc49851ecf7c74ad67928e7ca1d9342ec70e956e42
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
